MUC1 and non-small cell lung carcinoma: TG4010 is a therapeutic vaccine that includes a modified poxvirus engineered with MUC1 (a tumor‐associated antigen) and interleukin 2Phase II and Phase III trials to evaluate TG4010 with chemotherapy in advanced NSCLC patients were completed in July of 2014TG4010 with chemotherapy was found to improve progression‐free survival compared to chemotherapy aloneThe most common grade 3–4 adverse events as outlined by the National Cancer Institute Common Toxicity Criteria were found to be generally similar